The Measurement of Angiotensin-Converting Enzyme in Subjects Receiving Captopril
- 14 August 1980
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 303 (7) , 397
- https://doi.org/10.1056/nejm198008143030716
Abstract
To the Editor: Captopril1 , 2 causes long-term inhibition of angiotensin II formation, and studies have shown that it is effective in lowering blood pressure.3 4 5 At present there is no direct method to measure plasma levels of captopril, but it is possible to measure the activity of angiotensin-converting enzyme with substrate assay techniques.6 7 8 The degree to which the activity of angiotensin-converting enzyme is inhibited by captopril may provide an indirect way to assess the activity of the drug and patient compliance; however, variations in the degree of inhibition have been found.3 Therefore, when studying normal volunteers who had taken up to 100 . . .Keywords
This publication has 8 references indexed in Scilit:
- Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lungPublished by Elsevier ,2002
- Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme.BMJ, 1979
- Converting enzyme inhibition with an orally active compound in hypertensive man.Hypertension, 1978
- Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in ManNew England Journal of Medicine, 1978
- A simple radioassay for angiotensin-converting enzymeBiochemical Journal, 1977
- Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive AgentsScience, 1977
- A SPECIFIC ORALLY ACTIVE INHIBITOR OF ANGIOTENSIN-CONVERTING ENZYME IN MANThe Lancet, 1977
- A Sensitive Fluorimetric Assay for Serum Angiotensin-con venrting EnzymeAmerican Journal of Clinical Pathology, 1976